The comment was made after the US pharmaceutical giant Pfizer, together with its German partner BioNTech, announced that their experimental vaccine had shown more than 90% effectiveness, so a process for registration with the US Food and Drug Administration will soon be launched ( FDA).
At the same time, Dumpis says on social media Twitter that he is also very pleased with the announcement by Pfizer and BioNTech.
“A big day for science and humanity”
Jauns.lv has already reported that the vaccine has been tested on 43,500 people in six countries – the United States, Germany, Brazil, Argentina, South Africa and Turkey, and showed 90% protection, which developed seven days after receiving the second dose of the vaccine. This vaccination program involves one person receiving two doses, the second being given three weeks after the first.
“Today is a big day for science and humanity,” said Albert Burla, head of Pfizer.
“We are approaching a critical milestone in our vaccine development program at a time when the world needs it most, as the spread of the infection reaches new records, hospitals are close to overcrowding, and the economy is struggling,” he said.
Pfizer looks forward to receiving emergency vaccine approval from the U.S. authorities in the 16-85 age group. This will require two months of data for half of the approximately 44,000 clinical trial participants. These data could be collected at the end of the month.
Pfizer and BioNTech have a $ 1.95 billion deal with the U.S. government to supply 100 million units of vaccines. Negotiations have also begun with the governments of the European Union, Great Britain, Canada and Japan, writes Reuters.
To save time, companies had already started manufacturing the vaccine, not yet knowing if it was effective. As a result, representatives of pharmaceutical companies estimate that 50 million doses will be produced this year, which will be enough to protect 25 million people. Meanwhile, Pfizer is planning to produce 1.3 billion doses next year.
According to the FDA’s requirement, the Covid-19 vaccine must be at least 50% effective, so Pfizer’s statement concludes that this requirement is not only being met, but even exceeded.
The company found that an interim analysis of the study was carried out after 94 study participants became infected with Covid-19. The analysis was carried out to check how many of the people had received the vaccine against placebo. The company did not specify exactly how many people in the vaccine became infected with Covid-19, but the reported 90% effectiveness suggests that they cannot be more than eight of the 94 people who became ill with the coronavirus even though they were vaccinated, Reuters reported. As is well known, the vaccine is given in two doses, with the second dose given three weeks after the first.
To confirm the degree of effectiveness, Pfizer will continue trials until 164 people among the participants have developed Covid-19. Given the current increase in the spread of the infection in the United States, this mark could be reached in early December, said Bill Gruber, the company’s leading vaccine development scientist.
Others are currently reading
The most charming man in the kitchen – Mārtiņš Sirmais: “I am not interested in anything as deep as food”
VIDEO: “Our monument is left in the dark” – former President Valdis Zatlers invites people to donate to illuminate the Freedom Monument
–
–
–
Rebecca Salsabila Ibrahim and her husband “live a dream”, enjoying a holiday in Kurzeme
– .
